⌘K

Login Start Free

Home/Filings/4/0000891293-23-000001

4//SEC Filing

KIRSKE DAVID 4

Accession 0000891293-23-000001

CIK 0000891293other

View on SEC.gov Company Profile

Filed

Jan 2, 7:00 PM ET

Accepted

Jan 3, 6:36 PM ET

Size

31.0 KB

Accession

0000891293-23-000001

Insider Transaction Report

Form 4

Period: 2022-12-29

CTI BIOPHARMA CORPCTIC

See Remarks

Transactions

Sale
common stock
2022-12-30$6.00/sh−800$4,804→ 17,127 total
Sale
common stock
2022-12-30$6.01/sh−1,047$6,292→ 17,127 total
Sale
common stock
2022-12-30$6.00/sh−12,000$72,000→ 17,127 total
Award
common stock
2022-12-30$5.11/sh+214$1,093→ 17,127 total
Exercise/Conversion
common stock
2022-12-30$0.95/sh+12,000$11,387→ 29,127 total
Sale
common stock
2023-01-03$6.01/sh−27,021$162,423→ 17,127 total
Exercise/Conversion
common stock
2023-01-03$0.95/sh+27,021$25,640→ 44,148 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-12-29−13,174→ 311,084 total
Exercise: $0.95Exp: 2029-02-19→ Common Stock (13,174 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-12-30−1,047→ 297,237 total
Exercise: $0.95Exp: 2029-02-19→ Common Stock (1,047 underlying)
Exercise/Conversion
common stock
2022-12-29$0.95/sh+13,174$12,501→ 30,087 total
Exercise/Conversion
common stock
2022-12-30$0.95/sh+1,047$993→ 18,174 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-12-30−12,000→ 299,084 total
Exercise: $0.95Exp: 2029-02-19→ Common Stock (12,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-12-30−800→ 298,284 total
Exercise: $0.95Exp: 2029-02-19→ Common Stock (800 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-01-03−27,021→ 270,216 total
Exercise: $0.95Exp: 2029-02-19→ Common Stock (27,021 underlying)
Sale
common stock
2022-12-29$6.00/sh−13,174$79,044→ 16,913 total
Exercise/Conversion
common stock
2022-12-30$0.95/sh+800$759→ 17,927 total

Footnotes (4)

[F1]This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
[F2]Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
[F4]One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT

Issuer

CTI BIOPHARMA CORP

CIK 0000891293

Entity typeother

Related Parties

1

filerCIK 0001276750

Filing Metadata

Form type: 4
Filed: Jan 2, 7:00 PM ET
Accepted: Jan 3, 6:36 PM ET
Size: 31.0 KB

View on SEC.gov